SAL0112 / Shenzhen Salubris - LARVOL DELTA

Toxicology profile of a novel GLP1 receptor biased agonist-SAL0112 in nonhuman primates. (PubMed, Toxicol Appl Pharmacol) - "The NOAEL of SAL0112 is 150 mg/kg, providing an approximate safety margin of threefold. SAL0112 demonstrated a favorable safety profile in cynomolgus monkeys, with a substantial therapeutic window that supports the progression of this compound into clinical studies."

Journal • Cardiovascular • Diabetes • Genetic Disorders • Hematological Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Pharmacodynamic and pharmacokinetic profiles of a novel GLP-1 receptor biased agonist-SAL0112. (PubMed, Biomed Pharmacother) - "SAL0112 demonstrated potent and selective GLP-1 receptor biased agonism, effectively alleviating signs of type 2 diabetes in a mouse model. These promising findings pave the way for the advancement of SAL0112 into clinical trials."

Journal • PK/PD data • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus